Why consider China?
Specialist review across a long treatment history
The specialist resource
Ruijin’s published hematology platform links clinical care with research and structured disease management.
Read the supporting sourceWhat could this mean for your visit?
For previously treated myeloma, the useful starting point is a review of prior regimens, current assessments and a practical plan for continuing care at home.
Our planning interpretation of published information; individual suitability needs the receiving team’s assessment.Confirm before committing
Verify the exact available treatment, foreign-patient eligibility, full course costs and monitoring needs; research activity is not guaranteed access.
Start with a clear picture.
Before making travel plans, ask the receiving institution what it can assess from your records and what will require an in-person appointment. Treatment choices, costs and the length of a visit depend on the individual assessment.
Records to ask about
This starting list helps you organise information you already have. Confirm the exact requirements with the hospital.
- Pathology and relevant genetic reports
- Dated treatment and response history
- Recent imaging, blood tests and current medicines
Questions worth bringing
- Can the team review existing pathology and imaging before travel?
- Which options are routine care, and which would require a separate research eligibility review?
- How will local follow-up and any continuing treatment be coordinated?
Plan the practical details
Allow time for possible additional assessments, arrange language support if needed and check entry requirements using current official sources. Do not infer treatment suitability from another patient’s experience.
Understand your budget →Hospitals to research
These institutions publish relevant specialty information. Listings are research references, not confirmed referral arrangements.
Planning content updated 25 October 2026. Individual medical advice and treatment eligibility require review by a qualified receiving institution. This page has not been clinically reviewed.
Research source: Read the original source ↗. Source material does not establish a China Care partnership, appointment access or treatment endorsement.
Our editorial approach